Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Julie, Vanderpoel"'
Autor:
Lisa L. Dwyer, Pratyusha Vadagam, Julie Vanderpoel, Carol Cohen, Benjamin Lewing, Joseph Tkacz
Publikováno v:
Journal of Racial and Ethnic Health Disparities.
Background Although incidence and mortality of lung cancer have been decreasing, health disparities persist among historically marginalized Black, Hispanic, and Asian populations. A targeted literature review was performed to collate the evidence of
Autor:
Julie Vanderpoel, Bruno Emond, Isabelle Ghelerter, Katherine Milbers, Marie-Hélène Lafeuille, Patrick Lefebvre, Lorie A. Ellis
Publikováno v:
PharmacoEconomics - Open.
Publikováno v:
Advances in Therapy. 39:3347-3360
Approximately 15% of patients with non-small cell lung cancer (NSCLC) harbor an epidermal growth factor receptor mutation (EGFRm). Mutation testing (including EGFRm) is recommended for patients with advanced NSCLC (aNSCLC) prior to initiating first-l
Autor:
Julie Vanderpoel, Andrea L. Stevens, Bruno Emond, Marie-Hélène Lafeuille, Annalise Hilts, Patrick Lefebvre, Laura Morrison
Publikováno v:
Journal of medical economics. 25(1)
To assess the total cost of testing associated with next-generation sequencing (NGS) versus polymerase chain reaction (PCR) testing strategies among patients with metastatic non-small cell lung cancer (mNSCLC) from a Medicare and US commercial payer
Publikováno v:
Journal of Clinical Oncology. 39:298-298
298 Background: Guidelines recommend mutation testing prior to initiating first-line therapy (L1) for patients with advanced non-small cell lung cancer (aNSCLC), including testing for epidermal growth factor receptor (EGFR) mutations. Guidelines also
Publikováno v:
Clinical Therapeutics. 41:1080-1089.e5
Although biologics are effective in managing rheumatoid arthritis (RA), many patients experience at least one biologic switch during treatment. A switch in biologic treatment can occur for medical or nonmedical reasons. Changes to treatment regimens,
Autor:
Peter Wildgoose, Jeffrey Schein, Larry E. Fields, Julie Vanderpoel, Winnie W. Nelson, Jiyoon C. Choi, Chandrasekharra V. Damaraju
Publikováno v:
The American Journal of Cardiology. 112(4):509-512
This study determined the association between co-morbidities, including heart failure (HF) and time in therapeutic range (TTR), in patients with nonvalvular atrial fibrillation. Longitudinal patient-level anticoagulation management records collected
Autor:
Winnie W. Nelson, Jennifer Colby, J. Kluger, Craig I Coleman, Stacey M Coleman, Julie Vanderpoel, Jennifer M Scholle
Publikováno v:
International Journal of Clinical Practice. 66:984-990
Summary Background: The burden on caregivers providing support to atrial fibrillation (AF) patients has not been evaluated. Objective: To examine the interrelationship between unpaid caregiver, patient and thromboprophylaxis characteristics and careg
Autor:
Barbara Lennert, Julie Vanderpoel, Heidi C. Waters, Orsolya Lunacsek, Bijan Nejadnik, Damian H. Augustyn, R. Scott McKenzie, John Goff
Publikováno v:
Journal of Medical Economics. 15:45-52
Although Remicade (infliximab) is costly relative to non-biologic therapy, its impact on healthcare resource utilization and mucosal healing may make it a cost-effective option. This study aimed to compare gastrointestinal (GI)-related healthcare res
Autor:
Julie Vanderpoel, Douglas Gause, Thomas E. Delea, Jane Chang, Jennifer Cy Sung, Charles Makin, Timothy Sandman, Manjusha Gokhale, Paul Pinkston, J. Mark Jackson, Mohamed A. Hussein
Publikováno v:
Journal of Managed Care Pharmacy. 13:349-359
In the United States, pimecrolimus cream and tacrolimus ointment are approved as second-line therapy for short-term and intermittent noncontinuous long-term treatment of atopic dermatitis (AD) in nonimmunocompromised patients aged 2 years or older wh